| Literature DB >> 29225254 |
Tomoo Nagai1, Yoshiyuki Takase1, Akira Hamabe1, Hirotsugu Tabata1.
Abstract
Objective The purpose of this study was to present the recent clinical profiles and the real-world management of infective endocarditis (IE). Methods All medical records of patients with IE were reviewed retrospectively for their clinical data, including clinical presentation, laboratory results, blood cultures, echocardiographic findings, treatments and complications. Using the clinical data collected, we calculated the EuroSCORE II, the European risk score for adult cardiac surgery, the Charlson Comorbidity Index as a surrogate of comordibity, and the Katz Index as a surrogate of frailty. Results Thirty-eight patients were identified as having IE (24 men, age: 71.8±13.1 years). Congestive heart failure occurred in 16 patients (42%), stroke in 14 (50%), and systemic embolism in 5 (13%). The EuroSCORE II and Charlson Comorbidity Index were high (7.7±5.8% and 5.5±2.8%, respectively). The Katz Index was fair (5.5±1.4) before the onset but deteriorated to 2.8±2.7 at the time of establishing the diagnosis of IE (p<0.001). Early surgery was performed in 22 cases (61%). In-hospital death occurred in 10 cases (26%). A EuroSCORE II ≥9%, Staphylococcus aureus etiology, and a Charlson Comorbidity Index were suggested as determinants of in-hospital death (hazard ratios: 173.60, 9.31, 1.57, respectively). In contrast, early surgery was suggested as a determinant of the survival (hazard ratio: 0.04). The Charlson Comorbidity Index was also suggested as a determinant for selecting conservative management (odds ratio: 1.40). Conclusion Comorbidity may influence the treatment selection and outcome of elderly patients with IE.Entities:
Keywords: cardiac surgery; comorbidity; frailty; infective endocarditis
Mesh:
Year: 2017 PMID: 29225254 PMCID: PMC5827306 DOI: 10.2169/internalmedicine.9274-17
Source DB: PubMed Journal: Intern Med ISSN: 0918-2918 Impact factor: 1.271
Demographic Characteristics.
| Age, years | 71.8±13.1 (44-92) |
| Male gender | 24 (63%) |
| Predisposing background | |
| Decayed teeth/periodontitis | 4 (11%) |
| Chronic kidney disease | 5 (13%) |
| Diabetes mellitus requiring medication | 5 (13%) |
| Chronic liver disease | 8 (21%) |
| Cancer | 7 (18%) |
| Valvular heart disease | 15 (40%) |
| Cerebral vascular disease | 10 (26%) |
| Declined cognitive function | 11 (29%) |
| Healthcare-associated infection | 4 (11%) |
| Prosthetic valve infection | 5 (13%) |
| Intracardiac device infection | 4 (11%) |
| Symptoms at the onset | |
| Fever | 29 (76%) |
| Stroke | 4 (11%) |
| Systemic embolization | 2 (5%) |
| Congestive heart failure | 1 (3%) |
| Asymptomatic | 2 (5%) |
| Time interval from the onset to diagnosis, days# | 8 (19) |
| Less than 2 weeks | 23 (61%) |
| More than 3 months | 2 (5%) |
| EuroSCORE II2 | 7.7±5.8 |
| Charlson Comorbidity Index2 | 5.5±2.8 |
| Katz Index1 | 5.5±1.4 |
| Katz Index2 | 2.8±2.7* |
| Katz Index3 | 4.7±1.9† |
| Sequential organ failure assessment (SOFA) score2 | 7.0±2.8 |
| Duration of the hospitalization, days | 54.0±49.4 |
1before the onset, 2at the time of establishing the diagnosis, 3at the time of discharge (including only survived patients).
*p<0.05 vs. before the onset, †p<0.05 vs. at the time of establishing the diagnosis, #median value (interquartile range).
Microbiological and Echocardiographic Variables.
| Microbiological study | |
| Coagulase-negative staphylococci | 6 (16%) |
| 12 (32%) | |
| MSSA | 10 (26%) |
| MRSA | 2 (5%) |
| 2 (5%) | |
| Viridians Streptococci | 7 (18%) |
| HACEK group | 0 (0%) |
| Others | 5 (13%)* |
| Fungi | 0 (0%) |
| Culture negative | 6 (16%) |
| Echocardiographic study | |
| Left ventricular ejection fraction, % | 64.2±9.2 |
| Vegetation presentation | 31(82%) |
| Size of vegetation, mm | 12.1±4.9 |
| Size of vegetation >10 mm | 21 (55%) |
| Adhesion sites of vegetation | |
| Aortic valve | 11 (29%)† |
| Mitral valve | 18 (47%) |
| Tricuspid valve | 1 (3%) |
| Left ventricular wall | 2 (5%) |
| Pacemaker lead | 1 (3%) |
| Abscess formation | 7 (18%) |
| Perforation | 3 (8%) |
| Dehiscence | 3 (8%) |
| Fistula | 0 (0%) |
| Number of times of TTE required to establish the diagnosis | 1.4±0.7 |
| TEE performance | 28 (74%) |
*including one case with Streptococcus bovis, †including three bicuspid aortic valve cases.
MSSA: methicillin-sensitive Staphylococcus aureus, MRSA: methicillin-resistant Staphylococcus aureus, HACEK: Haemophilus species, Aggregatibacter species, Cardiobacteriumhominis, Eikenella corrodens and Kingella species, TTE: transthoracic echocardiography, TEE: transesophageal echocardiography
Management and Complications.
| Management | |
| Antibiotic treatment | |
| Empiric therapy | 6 (16%) |
| Absence of evident surgical indications | 6 (16%) |
| Surgical interventions | |
| Early surgery | 22 (58%) |
| Conservative management with elective surgery | 1 (3%) |
| Conservative management without surgery | 15 (40%) |
| Indications for early surgery | |
| Congestive heart failure >moderate | 8 |
| Persistent positive blood cultures after 1 week antibiotics | 1 |
| Recurrent emboli with persistent vegetation | 1 |
| Abscess formation | 5 |
| Dehiscence of the prosthesis | 3 |
| Size of vegetation >10 mm | 8 |
| Time interval from the diagnosis to the surgery, days# | 2.0 (5.3) |
| Complications | |
| Congestive heart failure | 16 (42%) |
| Stroke | 14 (37%)† |
| Systemic embolization | 5 (13%) |
| Coronary artery | 1 (3%) |
| Liver and spleen | 4 (11%) |
| Lower extremities | 1 (3%) |
| Persistent positive blood cultures | 4 (11%)* |
| In-hospital mortality | 10 (26%) |
| Cerebral embolism | 2 |
| Cerebral hemorrhage | 1* |
| Renal failure | 1 |
| Pneumonia | 4* |
| Congestive heart failure | 1 |
| Myocardial infarction | 1 |
*including one case after early surgery, †including one cerebral hemorrhage, #median value (interquartile range).
Univariate Analysis and Cox’s Proportional Hazard Model Analysis for Determining In- hospital Mortality.
| Death (n=10) | Survival (n=28) | p value | HR | 95% CI | p value | |
|---|---|---|---|---|---|---|
| Cancer | 5 (50%) | 2 (7%) | 0.027 | |||
| Chronic liver disease | 5 (50%) | 5 (18%) | 0.010 | |||
| Healthcare-associated IE | 3 (30%) | 1 (4%) | 0.019 | |||
| EuroSCORE II1 ≥9% | 5 (50%) | 6 (21%) | 0.087 | 173.60 | 6.74-4475.27 | 0.002 |
| Charlson Comorbidity Index1 | 7.6±2.5 | 4.7±2.7 | 0.004 | 1.57 | 1.06-2.31 | 0.023 |
| Katz Index1 | 1.0±1.9 | 3.4±2.7 | 0.015 | |||
| SOFA score1 | 8.4±3.2 | 6.5±2.5 | 0.060 | |||
|
| 6 (60%) | 6 (21%) | 0.024 | 9.31 | 1.86-46.70 | 0.007 |
| Vegetation presentation | 10 (100%) | 21 (75%) | 0.080 | |||
| Early surgery | 2 (20%) | 20 (71%) | 0.005 | 0.04 | 0.002-0.80 | 0.035 |
1at the time of establishing the diagnosis.
HR: hazard ratio, CI: confidence interval, IE: infective endocarditis, SOFA: sequential organ failure assessment
Figure.(a) The survival according to the management selection (early surgery vs. conservative management). (b) The survival according to EuroSCORE II ≥9. (c) The survival according to the presence of Staphylococcus aureus etiology. (d) The survival according to Charlson Comorbidity Index ≥3.
Univariate Analysis and Logistic Regression Analysis for Selection of Conservative Management.
| Conservative (n=16) | Early surgery (n=22) | p value | OR | 95% CI | p value | |
|---|---|---|---|---|---|---|
| Age | 77±12 | 68±13 | 0.034 | |||
| Diabetes mellitus requiring medication | 0 (0%) | 5 (23%) | 0.041 | |||
| Cancer | 5 (31%) | 2 (9%) | 0.082 | |||
| Declined cognitive function | 7 (44%) | 4 (18%) | 0.086 | |||
| Charlson Comorbidity Index2 | 6.8±3.0 | 4.6±2.4 | 0.016 | 1.40 | 1.03-1.91 | 0.031 |
| Katz Index1 | 5.0±2.1 | 5.9±0.5 | 0.055 | |||
| Katz Index2 | 1.7±2.6 | 3.5±2.6 | 0.036 | |||
| Empiric therapy of antibiotics | 0 (0%) | 6 (27%) | 0.023 | |||
| Absence of evident surgical indications | 6 (37%) | 0 (0%) | 0.002 |
1before the onset, 2at the time of establishing the diagnosis.
OR: odds ratio, CI: confidence interval